全文获取类型
收费全文 | 6080篇 |
免费 | 436篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 245篇 |
妇产科学 | 159篇 |
基础医学 | 953篇 |
口腔科学 | 53篇 |
临床医学 | 636篇 |
内科学 | 1169篇 |
皮肤病学 | 63篇 |
神经病学 | 704篇 |
特种医学 | 147篇 |
外科学 | 681篇 |
综合类 | 38篇 |
预防医学 | 654篇 |
眼科学 | 56篇 |
药学 | 470篇 |
中国医学 | 26篇 |
肿瘤学 | 430篇 |
出版年
2024年 | 5篇 |
2023年 | 36篇 |
2022年 | 62篇 |
2021年 | 167篇 |
2020年 | 100篇 |
2019年 | 151篇 |
2018年 | 173篇 |
2017年 | 128篇 |
2016年 | 142篇 |
2015年 | 174篇 |
2014年 | 203篇 |
2013年 | 311篇 |
2012年 | 429篇 |
2011年 | 505篇 |
2010年 | 264篇 |
2009年 | 253篇 |
2008年 | 416篇 |
2007年 | 428篇 |
2006年 | 392篇 |
2005年 | 398篇 |
2004年 | 392篇 |
2003年 | 359篇 |
2002年 | 326篇 |
2001年 | 51篇 |
2000年 | 32篇 |
1999年 | 46篇 |
1998年 | 67篇 |
1997年 | 63篇 |
1996年 | 61篇 |
1995年 | 44篇 |
1994年 | 39篇 |
1993年 | 34篇 |
1992年 | 22篇 |
1991年 | 19篇 |
1990年 | 21篇 |
1989年 | 21篇 |
1988年 | 18篇 |
1987年 | 21篇 |
1986年 | 11篇 |
1985年 | 13篇 |
1984年 | 23篇 |
1983年 | 13篇 |
1982年 | 18篇 |
1981年 | 14篇 |
1980年 | 20篇 |
1979年 | 11篇 |
1978年 | 12篇 |
1977年 | 5篇 |
1976年 | 4篇 |
1973年 | 5篇 |
排序方式: 共有6539条查询结果,搜索用时 328 毫秒
91.
Michel Ducreux Marc Ychou Agnès Laplanche Erick Gamelin Philippe Lasser Fares Husseini Fran?ois Quenet Frédéric Viret Jacques-Henri Jacob Valérie Boige Dominique Elias Jean-Robert Delperro Monique Luboinski 《Journal of clinical oncology》2005,23(22):4881-4887
PURPOSE: Isolated hepatic metastases of colorectal cancer constitute a frequent and serious therapeutic problem that has led to the evaluation of hepatic arterial infusion (HAI) of different drugs. Oxaliplatin combined with fluorouracil (FU) and leucovorin is effective in the treatment of colorectal cancer. In this context, a phase II study was conducted to evaluate concomitant administration of oxaliplatin by HAI and intravenous (IV) FU plus leucovorin according to the LV5FU2 protocol (leucovorin 200 mg/m(2), FU 400 mg/m(2) IV bolus, FU 600 mg/m(2) 22-hour continuous infusion on days 1 and 2 every 2 weeks). PATIENTS AND METHODS: Patients had metastatic colorectal cancer that was restricted to the liver and inoperable. The patients were not to have previously received oxaliplatin. After surgical insertion of a catheter in the hepatic artery, patients were treated with oxaliplatin 100 mg/m(2) HAI combined with FU + leucovorin IV according to the LV5FU2 protocol. Treatment was continued until disease progression or toxicity. Response was evaluated every 2 months. RESULTS: Twenty-eight patients were included, and 26 patients were treated. Two hundred courses of therapy were administered, and the median number of courses received was eight courses (range, zero to 20 courses). The most frequent toxicity consisted of neutropenia. The main toxicity related to HAI was pain. The intent-to-treat objective response rate was 64% (95% CI, 44% to 81%; 18 of 28 patients). With a median follow-up of 23 months, the median overall and disease-free survival times were 27 and 27 months, respectively. CONCLUSION: The combination of oxaliplatin HAI and FU + leucovorin according to the LV5FU2 protocol is feasible and effective in patients presenting with isolated hepatic metastases of colorectal cancer. 相似文献
92.
Dirk De Ruysscher Stofferinus Wanders Andre Minken Aniek Lumens Jacqueline Schiffelers Cissie Stultiens Serve Halders Liesbeth Boersma Angela van Baardwijk Tom Verschueren Monique Hochstenbag Gabriel Snoep Brad Wouters Sebastiaan Nijsten S?ren M Bentzen Marinus van Kroonenburgh Michel Ollers Philippe Lambin 《Radiotherapy and oncology》2005,77(1):5-10
BACKGROUND AND PURPOSE: To investigate the effect of radiotherapy planning with a dedicated combined PET-CT simulator of patients with locally advanced non-small cell lung cancer. PATIENTS AND METHODS: Twenty-one patients underwent a pre-treatment simulation on a dedicated hybrid PET-CT-simulator. For each patient, two 3D conformal treatment plans were made: one with a CT based PTV and one with a PET-CT based PTV, both to deliver 60Gy in 30 fractions. The maximum tolerable prescribed radiation dose for CT versus PET-CT PTV was calculated based on constraints for the lung, the oesophagus, and the spinal cord, and the Tumour Control Probability (TCP) was estimated. RESULTS: For the same toxicity levels of the lung, oesophagus and spinal cord, the dose could be increased from 55.2+/-2.0Gy with CT planning to 68.9+/-3.3Gy with the use of PET-CT (P=0.002), with corresponding TCP's of 6.3+/-1.5% for CT and 24.0+/-5.6% for PET-CT planning (P=0.01). CONCLUSIONS: The use of a combined dedicated PET-CT-simulator reduced radiation exposure of the oesophagus and the lung, and thus allowed significant radiation dose escalation whilst respecting all relevant normal tissue constraints. 相似文献
93.
Adrienne H Brouwers Peter F A Mulders Pieter H M de Mulder Wim J M van den Broek Wilhelmina C A M Buijs Carola Mala Frank B M Joosten Egbert Oosterwijk Otto C Boerman Frans H M Corstens Wim J G Oyen 《Journal of clinical oncology》2005,23(27):6540-6548
PURPOSE: A previous activity dose-escalation study using 131I-labeled chimeric monoclonal antibody cG250 in patients with progressive metastatic renal cell carcinoma (RCC) resulted in occasional therapeutic responses. The present study was designed to determine the safety and therapeutic efficacy of two sequential high-dose treatments with 131I-cG250. PATIENTS AND METHODS: Patients (n = 29) with progressive metastatic RCC received a low dose of (131)I-cG250 for assessment of preferential targeting of metastatic lesions, followed by the first radioimmunotherapy (RIT) with 2220 MBq/m2 131I-cG250 (n = 27) 1 week later. If no grade 4 hematologic toxicity was observed, a second low-dose 131I-cG250 (n = 20) was given 3 months later. When blood clearance was not accelerated, a second RIT of 131I-cG250 was administered at an activity-dose of 1110 MBq/m2 (n = 3) or 1665 MBq/m2 (n = 16). Patients were monitored weekly for toxicity, and tumor size was evaluated by computed tomography once every 3 months intervals. RESULTS: The maximum-tolerated dose (MTD) of the second RIT was 1,665 MBq/m2 because of dose-limiting hematological toxicity. Based on an intention-to-treat analysis, after two RIT treatments, the disease stabilized in five of 29 patients, whereas it remained progressive in 14 of 29 patients. Two patients received no RIT, and eight of 29 received only one 131I-cG250 RIT because of grade 4 hematologic toxicity, formation of human antichimeric antibodies, or disease progression. CONCLUSION: In patients with progressive end-stage RCC, the MTD of the second treatment was 75% of the MTD of the first RIT. In the majority of patients, two cycles of 131I-cG250 could be safely administered without severe toxicity. No objective responses were observed, but occasionally two RIT doses resulted in stabilization of previously progressive disease. 相似文献
94.
95.
The power of positive deviance 总被引:1,自引:0,他引:1
David R Marsh Dirk G Schroeder Kirk A Dearden Jerry Sternin Monique Sternin 《British medical journal》2004,329(7475):1177-1179
96.
97.
98.
99.
100.
Eric A.J. Bleeker Wim H. de Jong Robert E. Geertsma Monique Groenewold Evelyn H.W. Heugens Marjorie Koers-Jacquemijns Dik van de Meent Jan R. Popma Anton G. Rietveld Susan W.P. Wijnhoven Flemming R. Cassee Agnes G. Oomen 《Regulatory toxicology and pharmacology : RTP》2013,65(1):119-125
In recent years, an increasing number of applications and products containing or using nanomaterials have become available. This has raised concerns that some of these materials may introduce new risks for humans or the environment. A clear definition to discriminate nanomaterials from other materials is prerequisite to include provisions for nanomaterials in legislation. In October 2011 the European Commission published the ‘Recommendation on the definition of a nanomaterial’, primarily intended to provide unambiguous criteria to identify materials for which special regulatory provisions might apply, but also to promote consistency on the interpretation of the term ‘nanomaterial’. In this paper, the current status of various regulatory frameworks of the European Union with regard to nanomaterials is described, and major issues relevant for regulation of nanomaterials are discussed. This will contribute to better understanding the implications of the choices policy makers have to make in further regulation of nanomaterials. Potential issues that need to be addressed and areas of research in which science can contribute are indicated. These issues include awareness on situations in which nano-related risks may occur for materials that fall outside the definition, guidance and further development of measurement techniques, and dealing with changes during the life cycle. 相似文献